Nediljka Buljubasic
Cardiovascular Disease · Torrance, CANPI 1063482693
Payments from drug & device makers
Across 463 payments — averaging $1013.38 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk AS$459K
- Novartis$9K
- Novo Nordisk$936
- Scpharmaceuticals Inc.$81
- Lantheus Medical Imaging, Inc.$13
Across 8 payments — averaging $208.35 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Novo Nordisk AS$2K
What the payments were for
- Travel & lodging$1,31349%
- Food & beverage$43416%
- Education$93635%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk AS | 430 | $459,408 |
| Novartis | 2 | $8,757 |
| Novo Nordisk | 29 | $936 |
| Scpharmaceuticals Inc. | 1 | $81 |
| Lantheus Medical Imaging, Inc. | 1 | $13 |
How this compares
$469,195 in reported general payments places this provider in the 95th percentile of 2,184 cardiovascular disease providers in California.
Other cardiovascular disease in Torrance
- Matthew BudoffTorrance$11.3M
- Ronald OudizTorrance$2.6M
- William FrenchTorrance$2.2M
- Rushi ParikhTorrance$731K
- Ted LoveHillsborough$102.8M
- Lori DanielsSan Diego$10.2M
- Paul KurthSanta Barbara$6.1M
- Michael BlumSan Francisco$5.5M
- Tony ChouSan Francisco$5.2M
- Jason RogersSacramento$5.1M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.